hdl-c

Ibrolipim (NO-1886) 是口服具有活力的脂蛋白脂肪酶 (LPL) 激活剂。它能够降低血浆甘油三酸酯，增加高密度脂蛋白胆固醇水平，具有肾保护和降血脂的作用。

GW590735 是一种有效的选择性 PPARα 激动剂，对 PPARα 的 EC50 为 4 nM，比 PPARδ 和 PPARγ 的选择性至少高 500 倍。 GW590735 可用于血脂异常研究。

Icosabutate (NST-4016) 是一种具有口服活性的二十碳五烯酸的衍生物，可抑制 NASH 的肝脏炎症和纤维化，可改善他汀类药物治疗的残留高甘油三酯血症患者的心血管风险状况，降低甘油三脂，可用于研究肝纤维化和动脉粥样硬化。

Gemfibrozil (CI-719) 是一种PPAR-α激活剂，可作为降脂药。它也是P450非选择性抑制剂，对 CYP2C9、2C19、2C8 和 1A2 的Ki 值分别为 5.8、24、69 和 82 μM。

Polydatin (Piceid) 是从传统中药虎杖根中提取的一种天然产物，在多个实验模型中具有抗炎作用。它可抑制 G6PD，并诱导氧化和内质网应激。

CETP-IN-3 is an inhibitor of the plasma glycoprotein cholesterol ester transfer protein (CETP), elevating HDL-C through inhibition of CETP.

Gemcabene calcium , a first-in-class lipid-lowering agent, lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C) andexerting anti-inflammatory activity, lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP).

BLT-1 是一种氨基硫脲铜螯合剂，是一种选择性清除受体 B1 型 (SR-BI) 抑制剂，抑制高密度脂蛋白 (HDL) 和 SR-BI 介导的细胞之间的脂质转移。

LY518674 (LY-674) 是一种高效、选择性的 PPARα 激动剂，对人 PPARα 作用的 EC50 值为 42 nM。LY518674 能降低甘油三酸酯，增加 HDL-C，可用于研究动脉粥样硬化。

Potent cholesteryl ester transfer protein (CETP) inhibitor (IC50 = 4 nM in an enzyme-based scintillation proximity assay). Inhibits cholesteryl ester transfer and increases HDL-C levels in vivo. Orally bioavailable. Qiao et al (2015) Triphenylethanamine derivatives as cholesteryl ester transfer protein inhibitors: discovery of N-[(1R)-1-(3-cyclopropoxy-4-fluorophenyl)-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-2-phenylethyl]-4-fluoro-3-(trifluoromethyl)benzamid J.Med.Chem. 58 9010 PMID:26524347

Methyl protodioscin (Smilax saponin B) 是一种甾二糖苷，能诱导细胞周期阻滞，具有抗肿瘤活性。

Obicetrapib potassium is a cholesteryl ester transfer protein (CETP) inhibitor. CETP inhibitors substantially increase the concentration of high-density lipoprotein cholesterol (HDL-C), which may have a possible beneficial effect for cardiovascular disease risk reduction.

Obicetrapib calcium is a cholesteryl ester transfer protein (CETP) inhibitor. CETP inhibitors substantially increase the concentration of high-density lipoprotein cholesterol (HDL-C), which may have a possible beneficial effect for cardiovascular disease risk reduction.

Obicetrapib sodium is a cholesteryl ester transfer protein (CETP) inhibitor. CETP inhibitors substantially increase the concentration of high-density lipoprotein cholesterol (HDL-C), which may have a possible beneficial effect for cardiovascular disease risk reduction.

Bambuterol is a prodrug of β2-agonist commonly used for the treatment of asthma and chronic obstructive pulmonary disease (COPD) with the advantage of once daily dosing and favorable side effect profile. Administration of a single-dose of R-bambuterol resulted in dose-dependent reductions in the levels of plasma LDL-C, high-density lipoprotein cholesterol (HDL-C), total cholesterol (TC), apolipoprotein B (ApoB) and apolipoprotein A1 (ApoA1) at Tmax. R-bambuterol can lower the plasma levels of LDL-C, and marginally raise the ratio of ApoA1 ApoB (indicator of HDL-C LDL-C) with both a single dose and multiple doses. R-bambuterol was more potent in LDL-C lowering than rac-bambutero

Ebronucimab（伊努西单抗）是一种靶向PCSK9的 IgG1抗体，能够降低LDL-C、TC、Non-HDL-C和 ApoB，提高，HDL-C和Apo A-I，用于治疗原发性高胆固醇血症和混合性高脂血症和杂合性家族性高胆固醇血症（HeFH）。

RG33是一种33个氨基酸的合成肽，与apolipoprotein A1 (ApoA1)的C-末端域中两个Y类螺旋的209-219和220-241氨基酸相对应。它能溶解含有1,2-dimyristoyl-sn-glycero-3-PC (DMPC)的多层囊泡(MLVs)，形成重组HDL。与脂质结合的RG33在J774巨噬细胞中诱导胆固醇外流。RG33 (12 mg/kg)可降低胰岛素抵抗性小鼠的血糖水平。